Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.290
+1.13013.85%
Volume:193.00M
Turnover:1.73B
Market Cap:107.04B
PE:24.16
High:9.330
Open:8.230
Low:8.100
Close:8.160
52wk High:11.454
52wk Low:4.502
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.54
T/O Rate:1.68%
Dividend:0.24
Dividend Rate:2.58%
EPS(LYR):0.385
ROE:11.33%
ROA:5.44%
PB:2.85
PE(LYR):24.16
PS:3.64

Loading ...

BRIEF-CSPC Pharmaceutical Logs FY Net Income Attributable RMB 3,882.1 Mln

Reuters
·
Mar 25

CSPC Pharmaceutical Group proposes final dividend of HKD 0.15 per share for FY2025

Reuters
·
Mar 25

CSPC Pharmaceutical Group FY Net Income Attributable RMB 3,882.1 Million

THOMSON REUTERS
·
Mar 25

CSPC Pharmaceutical Group FY Revenue RMB 20,583.7 Million

THOMSON REUTERS
·
Mar 25

CSPC Pharmaceutical posts FY2025 revenue drop of 10.4%; announces HKD 0.15 final dividend per share

Reuters
·
Mar 25

CSPC underlying profit attributable to shareholders drops 24.5% to RMB 3.5 billion in FY2025; revenue falls 10.4% to RMB 26.0 billion

Reuters
·
Mar 25

BRIEF-CSPC Pharmaceutical Aprepitant Injection (4.4Ml32Mg) Obtains Drug Registration Approval In China

Reuters
·
Mar 23

CSPC Pharma Gets China Nod for Postoperative Nausea Drug Registration

MT Newswires Live
·
Mar 23

CSPC Pharma Gains NMPA Clearance for New-Generation Aprepitant Injection Targeting Post-Operative Nausea

Bulletin Express
·
Mar 23

CSPC PHARMA's Aprepitant Injection Secures Drug Registration Approval

Stock News
·
Mar 23

CSPC wins China NMPA approval for 32mg aprepitant injection

Reuters
·
Mar 23

CSPC Pharmaceutical - Approval Granted by Nmpa

THOMSON REUTERS
·
Mar 23

CSPC Pharmaceutical - Aprepitant Injection (4.4Ml:32Mg) Obtains Drug Registration Approval in China

THOMSON REUTERS
·
Mar 23

CSPC Pharmaceutical Group Stock Sheds 6.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 23

Zhejiang Starry to Acquire 20% Stake in Ruishi Pharma for 10 Million Yuan to Boost CMO Capacity

Stock News
·
Mar 23

CSPC Pharmaceutical Receives Chinese Clinical Trial Approval for GLP-1/GIP Dual Agonist

Stock News
·
Mar 20

BRIEF-Cspc Pharmaceutical Says GLP-1/GIP Receptor Dual-Biased Agonist Polypeptide Injection Obtains Clinical Trial Approval In China

Reuters
·
Mar 20

CSPC Pharma wins China clinical trial approval for SYH2082 injection

Reuters
·
Mar 20

CSPC Pharmaceutical - Glp-1/Gip Receptor Dual-Biased Agonist Polypeptide Long-Acting Injection (Syh2082 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Mar 20

DIARY-Hong Kong corporate earnings week ahead

Reuters
·
Mar 20